Nkarta, Inc. (NKTX) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 South San Francisco, CA, 美国. 现任CEO为 Paul J. Hastings.
NKTX 拥有 IPO日期为 2020-07-10, 157 名全职员工, 在 NASDAQ Global Select, 市值为 $172.52M.
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
